Table 2. The results of meta-analysis on NSCLC overall survival and p16 methylation.
| Pts number | HR (95%CI) | Heterogeneity | |||
| chi-squared (d.f.) | p-value | I2 | |||
| All studies | 2432 | 1.36 (1.08–1.73) | 41.60 (d.f. = 18) | 0.001 | 56.7% |
| Subgroups | |||||
| Detecting method | |||||
| MSP | 1821 | 1.40 (1.02–1.92) | 26.69 (d.f. = 14) | 0.021 | 47.5% |
| Q-MSP | 611 | 1.26 (0.87–1.82) | 6.80 (d.f. = 3) | 0.079 | 55.9% |
| Stage | |||||
| I | 242 | 2.53(1.26–5.11) | 0.03 (d.f. = 1) | 0.865 | 0.0% |
| I–II | 202 | 1.28(0.79–2.06) | 0.46 (d.f. = 1) | 0.498 | 0.0% |
| I–III | 805 | 1.61(1.19–2.19) | 4.57 (d.f. = 5) | 0.470 | 0.0% |
| I–IV | 1091 | 1.00(0.71–1.41) | 11.39 (d.f. = 6) | 0.077 | 47.3% |
| Histology | |||||
| NSCLC | 2303 | 1.41(1.10–1.79) | 37.28 (d.f. = 16) | 0.002 | 57.1% |
| ADC | 412 | 1.56(0.84–2.88) | 9.76(d.f. = 5) | 0.082 | 48.8% |
| Sample type | |||||
| Fresh tissue | 1736 | 1.50(1.11–2.01) | 20.64(d.f. = 13) | 0.080 | 37.0% |
| FFPE tissue | 604 | 1.10(0.77–1.57) | 6.50(d.f. = 3) | 0.090 | 53.8% |
MSP, Methylation-specific PCR; Q-MSP, quantitative methylation-specific PCR; FFPE, formalin-fixed paraffin-embedded; ADC, adenocarcinoma; Pts, patients.